EEF1A1/EEF1A2/EEF1A1P5 Antibody

What are the primary differences between EEF1A1 and EEF1A2, and why is distinguishing them important in research?

EEF1A1 and EEF1A2 are paralogous proteins with high sequence similarity (90% identical, 98% similar) but exhibit mutually exclusive expression patterns in normal tissues . While often collectively referred to as "eEF1A" in scientific literature, their expression is developmentally regulated and tissue-specific:

• EEF1A1 is widely expressed in brain, placenta, lung, liver, kidney, and pancreas

• EEF1A2 expression is primarily restricted to postmitotic cells such as myocytes and neurons

Distinguishing between these proteins is critical because:

• Their dysregulation has distinct implications in disease states

• EEF1A2 overexpression has been documented in multiple cancer types, making it a potential biomarker or therapeutic target

• Loss of EEF1A2 expression is associated with neurodegenerative pathology, as demonstrated in Wasted mice models

Research requiring isoform discrimination should employ specific antibodies validated for selectivity between these highly similar proteins.

Verifying antibody specificity is crucial for these highly similar proteins. Recommended validation approaches include:

• CRISPR/Cas9 knockdown controls: Knockdown of individual EEF1A methyltransferases has been used to confirm antibody specificity by demonstrating depletion of bands recognized by isoform-specific antibodies

• Western blot with recombinant protein standards: Include purified recombinant EEF1A1 and EEF1A2 proteins as positive controls

• Peptide competition assays: Pre-incubation with the immunizing peptide should abolish specific binding

• Cross-validation with multiple antibodies: Use different antibodies targeting distinct epitopes to confirm results

• Immunoprecipitation followed by mass spectrometry: This approach definitively identifies the captured protein and can reveal potential cross-reactivity

Research by Jakobsson et al. demonstrated the importance of validation by using CRISPR/Cas9 to knockdown specific EEF1A lysine methyltransferases, confirming antibody specificity through the depletion of cognate methylation sites .

How can EEF1A1/EEF1A2 antibodies be used to investigate methylation-dependent functions in translation regulation?

EEF1A proteins undergo extensive post-translational modifications (PTMs), particularly methylation, which affects their function in translation. Recent research has developed methyl-specific antibodies to investigate these modifications:

• Methylation site-specific antibodies: Antibodies targeting specific methylation sites (e.g., K36me2, K55me3, K79me2, K165me3, and K318me3) have been developed and validated for studying methylation dynamics

• Methyltransferase relationship mapping: Using these antibodies in combination with knockdown of specific methyltransferases (METTL13, METTL10, eEF1AKMT4, N6AMT2) reveals regulatory relationships and crosstalk between different methylation sites

• Tissue-specific methylation patterns: IHC applications with these antibodies have revealed potential age-related changes in methylation patterns in muscle tissue

This approach has revealed complex regulatory relationships, including how knockdown of N6AMT2 impacts eEF1AK36me3 levels, while METTL10 depletion affects eEF1AK79me3 levels, suggesting crosstalk between methylation sites that may coordinate translation efficiency .

What role do EEF1A1/EEF1A2 antibodies play in investigating heat shock response mechanisms?

EEF1A1 has been shown to participate in the entire heat shock response (HSR) process, from transcription through translation. Antibodies have helped elucidate this mechanism:

• Chromatin Immunoprecipitation (ChIP): EEF1A1 antibodies in ChIP experiments demonstrate direct binding of EEF1A1 to the HSP70 promoter both before and after heat shock

• Co-immunoprecipitation: EEF1A1 antibodies can precipitate HSF1 (heat shock factor 1) complexes, revealing a physical interaction that enhances HSF1 DNA binding upon heat shock

• Electrophoretic Mobility Shift Assays (EMSA): Addition of EEF1A1 antibodies causes a supershift in HSF1-HSE complexes, confirming the presence of EEF1A1 in the DNA-bound complex

These techniques revealed that EEF1A1 (but not the tissue-specific EEF1A2) activates transcription of HSP70 by recruiting HSF1 to its promoter, then associates with elongating RNA polymerase II and the 3'UTR of HSP70 mRNA to stabilize and facilitate its transport .

How can researchers use EEF1A antibodies to differentiate between tissue-specific expression patterns in normal versus cancerous tissues?

EEF1A1 and EEF1A2 show distinct tissue expression patterns that are often dysregulated in cancer. Approaches utilizing antibodies include:

• Tissue microarray (TMA) analysis: Using isoform-specific antibodies on TMAs containing normal and cancerous tissues to quantify expression changes

• Cancer subtype characterization: Immunohistochemical analysis of different cancer subtypes (e.g., basal, luminal, HER2+ in breast cancer) reveals differential expression patterns

• Correlation with clinical outcomes: Staining intensity can be correlated with patient survival data to assess prognostic value

Analysis of The Cancer Genome Atlas (TCGA) data revealed that:

• EEF1A2 expression is significantly increased in breast cancer compared to normal tissue, particularly in luminal A, luminal B, and HER2+ subtypes

• EEF1A2 is overexpressed in clear cell carcinoma of the ovary

• In lung cancer, EEF1A2 shows differential expression between adenocarcinoma and squamous cell subtypes

• High EEF1A2 expression correlates with poor prognosis in certain cancer types

These patterns can be confirmed at the protein level using specific antibodies in immunohistochemistry applications.

What are the optimal protocols for using EEF1A1/EEF1A2 antibodies in immunohistochemistry (IHC) applications?

For successful IHC applications with EEF1A antibodies, consider the following protocol recommendations:

• Fixation: Formalin-fixed, paraffin-embedded tissues are commonly used, though optimal fixation conditions may vary by tissue type

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is generally effective for exposing EEF1A epitopes

• Blocking: Use 5% normal serum from the same species as the secondary antibody to reduce background

• Primary antibody incubation:

  • Dilution: 1:100-1:500 (antibody dependent)

  • Temperature: 4°C

  • Duration: Overnight (12-16 hours)

• Controls: Include positive controls (tissues known to express the target) and negative controls (antibody diluent without primary antibody)

Research by Jakobsson et al. successfully employed EEF1A methyl-specific antibodies in IHC applications using mouse colon and skeletal muscle tissues as well as human pancreatic ductal adenocarcinoma samples, demonstrating the versatility of these antibodies across species and tissue types .

What techniques can resolve contradictory expression data between mRNA levels and protein detection using EEF1A antibodies?

Resolving discrepancies between mRNA and protein levels of EEF1A isoforms requires an integrated approach:

• Quantitative PCR with isoform-specific primers: Design primers that target unique regions to distinguish between highly similar transcripts

• Multiple antibodies targeting different epitopes: Use antibodies recognizing different regions of the protein to confirm specificity

• Mass spectrometry validation: Identify unique peptides that distinguish between isoforms

• Subcellular fractionation: Determine if differences are due to protein localization rather than total expression

• Polysome profiling: Assess if transcripts are actively translated

Studies have noted interesting contradictions, such as TCGA datasets showing reduced EEF1A2 expression in ovarian cancer compared to GTEx normal tissue, which contradicts other studies showing overexpression. These discrepancies may be attributed to "sample heterogeneity, normalization techniques or statistical methodologies, sample size, and clinical variations" .

How should researchers interpret post-translational modifications when using EEF1A antibodies?

Interpreting post-translational modifications of EEF1A proteins requires careful consideration:

• Modification-specific antibodies: Use antibodies that specifically recognize phosphorylated, methylated, or acetylated forms of EEF1A

• Sample preparation: Preserve modifications by including phosphatase inhibitors, deacetylase inhibitors, or other relevant inhibitors during extraction

• Western blot appearance: Modified forms may appear as multiple bands or band shifts compared to unmodified proteins

• Physiological relevance: Correlate modification patterns with biological processes or disease states

• Cross-validation: Confirm antibody findings with mass spectrometry to definitively identify modifications

Research has shown complex crosstalk between different methylation sites on EEF1A, where "knockdown of N6AMT2 impacted eEF1AK36me3 levels, whereas METTL10 depletion impacted eEF1AK79me3 levels," revealing regulatory relationships between modifications that may coordinate function .

How can researchers address non-specific binding issues with EEF1A antibodies?

EEF1A proteins are highly abundant (>1% of total cellular protein) , which can lead to background issues. Strategies to address this include:

• Pre-absorption with recombinant protein: For cross-reactive antibodies, pre-incubate with the non-target isoform to improve specificity

• Optimizing blocking conditions: Extend blocking time or use alternative blockers (e.g., 5% milk vs. BSA)

• Secondary antibody optimization: Test different species or formats of secondary antibodies

• Inclusion of detergents: Adding 0.1-0.3% Triton X-100 can reduce non-specific membrane binding

• Validation with knockout/knockdown controls: Compare staining with CRISPR-modified cells lacking the target protein

The experimental assay coefficient of variability (CV) should be calculated and reported using the standard deviation divided by the mean (×100) to assess consistency and reliability of results .

What approaches are recommended for studying the relationship between EEF1A isoforms and cancer progression?

To investigate EEF1A's role in cancer using antibody-based approaches:

• Tissue microarrays with clinical follow-up: Correlate expression with patient outcomes across cancer stages

• Multi-parameter immunofluorescence: Co-stain for EEF1A isoforms alongside cancer markers and signaling proteins

• Circulating tumor cell (CTC) analysis: Examine EEF1A expression in CTCs as potential biomarkers

• Patient-derived xenograft (PDX) models: Monitor expression changes during tumor progression and treatment

• Therapeutic targeting validation: Use antibodies to verify target engagement in drug development

Research has revealed complex patterns where EEF1A2 overexpression correlates with poor prognosis in some cancers (e.g., lung adenocarcinoma) but correlates with increased survival in others (e.g., serous ovarian tumors) . These contradictions highlight the need for careful analysis within specific cancer subtypes.

What are the best approaches for developing and validating novel antibodies against specific EEF1A post-translational modifications?

Development of site-specific modification antibodies requires:

• Peptide design strategies:

  • Synthesize peptides containing the specific modification (e.g., methylated lysine)

  • Include 7-15 amino acids surrounding the modification site

  • Use carrier proteins like KLH for immunization

• Immunization and screening protocols:

  • Immunize rabbits with modified peptides

  • Screen antibodies against both modified and unmodified peptides

  • Test for cross-reactivity with related modifications

• Validation approaches:

  • Use knockout/knockdown of specific methyltransferases

  • Compare with mass spectrometry data

  • Test across multiple applications (WB, IHC, ChIP)

• Cross-validation using independent epitopes:

  • Develop antibodies against different regions containing the same modification

  • Compare results across antibodies to confirm specificity

Jakobsson et al. demonstrated the effectiveness of this approach by developing antibodies against five major eEF1A methylation sites (K36me2, K55me3, K79me2, K165me3, and K318me3) that showed high specificity in Western blot, immunoprecipitation, and immunohistochemistry applications .

How might emerging technologies enhance the utility of EEF1A antibodies in single-cell analysis?

Emerging technologies that will advance EEF1A antibody applications include:

• Mass cytometry (CyTOF): Metal-conjugated EEF1A antibodies can be multiplexed with dozens of other markers to profile individual cells in heterogeneous populations

• Single-cell Western blot: Miniaturized Western blot systems could detect EEF1A isoforms in individual cells

• Proximity ligation assays (PLA): These can detect protein-protein interactions involving EEF1A proteins at the single-cell level

• Spatial transcriptomics with protein co-detection: Combining RNA sequencing with antibody detection to correlate mRNA and protein levels in tissue contexts

• Engineered antibody fragments: Single-domain antibodies or nanobodies against EEF1A isoforms could improve penetration into cellular compartments

These approaches will be particularly valuable for understanding the role of EEF1A in heterogeneous tissues and during dynamic processes like development, aging, and disease progression.

What role might EEF1A1/EEF1A2 antibodies play in investigating aging-related protein synthesis changes?

EEF1A antibodies are becoming important tools in aging research:

• Age-related methylation changes: Methyl-specific antibodies have demonstrated that "several eEF1A methylation events decrease in aged muscle tissue"

• Tissue-specific aging patterns: Antibodies can reveal how EEF1A changes across different tissues during aging

• Models of accelerated aging: Compare EEF1A modifications in normal aging versus disease models of accelerated aging

• Interventions affecting lifespan: Monitor EEF1A changes in response to interventions that extend lifespan

• Correlation with proteostasis markers: Co-staining for EEF1A alongside markers of protein aggregation, autophagy, or stress responses

Research suggests that EEF1A methylation may play a role "in aging biology via protein synthesis regulation," with observed decreases in methylation potentially contributing to age-related declines in translation fidelity and efficiency .

How can researchers integrate EEF1A antibody data with functional studies to better understand canonical versus non-canonical roles?

Integrating antibody-based detection with functional studies requires:

• Domain-specific antibodies: Develop antibodies targeting functional domains to correlate structure with function

• Conformation-specific antibodies: Generate antibodies that specifically recognize GTP-bound versus GDP-bound states

• Proximity-based labeling: Use antibodies conjugated to enzymes like APEX2 or TurboID to identify proximal interacting proteins in different states

• Live-cell imaging: Correlate antibody-based fixed-cell data with live imaging using fluorescent protein fusions

• Structure-function correlation: Map antibody epitopes to resolved structures to understand how binding affects function

Research has revealed that EEF1A1 has multiple non-canonical functions beyond translation, including "regulation of cotranslational degradation of nascent proteins, actin and microtubule organization, nuclear transport, and other functions" . Additionally, it participates in the heat shock response by binding directly to the HSP70 promoter and facilitating transcription . Understanding these diverse roles requires integrating antibody-based detection with functional assays.